Nutriband enters amended $5M credit line at 7% interest for AVERSA Fentanyl

NutriBand Inc.

$5M credit line facility amended as of June 1, 2026, replacing prior $5M facility expiring July 2026.
Interest at 7% per annum; no conversion rights for lender into common stock.
Proceeds for commercialization of AVERSA Fentanyl, including FDA submission and manufacturing costs with Kindeva Drug Delivery.
Maturity date July 1, 2029; advances allowed only after commencement of NDA-related work with Kindeva.

item 1.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

NutriBand Inc. amended a credit facility valued at $5,000,000 (effective 2026-06-01).

Action: amendment
Agreement: credit facility
Value: $5,000,000
Effective: 2026-06-01

Exact text from the filing

The Company on June 1, 2026 entered into an amended three-year $5,000,000 credit line facility (replacing the $5,000,000 facility (that we had entered into on March 19, 2023, and scheduled to expire July 13, 2026), drawdowns under which bear interest at the rate of 7% per annum.

View on SEC.gov

628 material agreements filed in the last 30 days. Browse all material agreements →

NutriBand Inc. filing history →

Source: SEC EDGAR

accession 0001213900-26-070378

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.